Taro Pharmaceutical reports Q4 EPS 19c vs. 70c last year

Reports Q4 revenue $139.2M,versus $138,984 in last year’s quarter. Cash flow used in operations for the nine months ended December 31 was $24.9M compared to $200M for the nine months ended December 31 Excluding the impact from the settlement payments and settlement and loss contingencies charges impacting both periods, cash flow provided by operations was $50.4M compared to $124.6M for the nine months ended December 31. As of December 31 , cash and cash equivalents, short-term bank deposits and marketable securities, both short- and long-term, decreased $54.6M to $1.2B from March 31, principally the result of settlement payments.